

Joseph Jankovic

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6593861/joseph-jankovic-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

417
papers

20,987
citations

75
h-index

130
g-index

656
ext. papers

25,511
ext. citations

6.4
avg, IF

7.67
L-index

#	Paper	IF	Citations
417	Phenomenology and classification of dystonia: a consensus update. <i>Movement Disorders</i> , 2013 , 28, 863-73		1217
416	A double-blind, delayed-start trial of rasagiline in Parkinson's disease. <i>New England Journal of Medicine</i> , 2009 , 361, 1268-78	59.2	694
415	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. <i>Lancet Neurology</i> , 2019 , 18, 1091-1102	24.1	562
414	Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. <i>Lancet Neurology</i> , 2010 , 9, 1164-1172	24.1	498
413	Paroxysmal dyskinesias: clinical features and classification. <i>Annals of Neurology</i> , 1995 , 38, 571-9	9.4	462
412	Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. <i>Movement Disorders</i> , 2005 , 20 Suppl 11, S11-6	7	350
411	Parkinson disease subtypes. <i>JAMA Neurology</i> , 2014 , 71, 499-504	17.2	310
410	Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. <i>Annals of Neurology</i> , 1983 , 13, 402-11	9.4	293
409	Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. <i>Neurology</i> , 2016 , 86, 1818-26	6.5	291
408	Hemifacial spasm: clinical findings and treatment. <i>Muscle and Nerve</i> , 1998 , 21, 1740-7	3.4	261
407	The genetics of Parkinson disease. <i>Ageing Research Reviews</i> , 2018 , 42, 72-85	12	254
406	Treatment of dystonia. <i>Lancet Neurology</i> , 2006 , 5, 864-72	24.1	245
405	Sensory aspects of movement disorders. <i>Lancet Neurology</i> , 2014 , 13, 100-12	24.1	236
404	Premonitory sensory phenomenon in Tourette's syndrome. <i>Movement Disorders</i> , 2003 , 18, 1530-3	7	226
403	Treatment of hyperkinetic movement disorders. <i>Lancet Neurology</i> , 2009 , 8, 844-56	24.1	222
402	Lower body parkinsonism: evidence for vascular etiology. <i>Movement Disorders</i> , 1989 , 4, 249-60	7	210
401	Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. <i>Brain</i> , 2017 , 140, 3191-3203	11.2	209

400	Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 40-50	27.4	191
399	Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. <i>Annals of Neurology</i> , 2015 , 78, 248-57	9.4	190
398	Can peripheral trauma induce dystonia and other movement disorders? Yes!. <i>Movement Disorders</i> , 2001 , 16, 7-12	7	188
397	Long-term botulinum toxin efficacy, safety, and immunogenicity. <i>Movement Disorders</i> , 2005 , 20, 592-7	7	187
396	Current approaches to the treatment of Parkinson's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2008 , 4, 743-57	3.1	184
395	The role of FUS gene variants in neurodegenerative diseases. <i>Nature Reviews Neurology</i> , 2014 , 10, 337-48	5	180
394	Natural history of multiple system atrophy in the USA: a prospective cohort study. <i>Lancet Neurology</i> , 2015 , 14, 710-9	24.1	169
393	Botulinum toxin in the treatment of tics. <i>Archives of Neurology</i> , 2000 , 57, 1190-3		163
392	Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. <i>Movement Disorders</i> , 2008 , 23, 1353-60	7	158
391	Essential tremor: a heterogenous disorder. <i>Movement Disorders</i> , 2002 , 17, 638-44	7	157
390	Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. <i>Neurology</i> , 2019 , 92, 896-906	6.5	154
389	Tourette syndrome: evolving concepts. <i>Movement Disorders</i> , 2011 , 26, 1149-56	7	154
388	Malignant Tourette syndrome. <i>Movement Disorders</i> , 2007 , 22, 1743-50	7	147
387	Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti- α -Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2018 , 75, 1206-1214	17.2	144
386	Dopa-responsive dystonia--clinical and genetic heterogeneity. <i>Nature Reviews Neurology</i> , 2015 , 11, 414-24	24.5	142
385	The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1460-1477	5.3	142
384	Therapies in Parkinson's disease. <i>Current Opinion in Neurology</i> , 2012 , 25, 433-47	7.1	141
383	Medical management of levodopa-associated motor complications in patients with Parkinson's disease. <i>CNS Drugs</i> , 2007 , 21, 677-92	6.7	141

382	Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. <i>Annals of Neurology</i> , 1982 , 11, 41-7	9.4	140
381	Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and Synuclein mechanisms. <i>Movement Disorders</i> , 2019 , 34, 866-875	7	136
380	Searching for a relationship between manganese and welding and Parkinson's disease. <i>Neurology</i> , 2005 , 64, 2021-8	6.5	135
379	Association between essential tremor and Parkinson's disease. <i>Annals of Neurology</i> , 1985 , 17, 329-33	9.4	131
378	Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. <i>Neurogenetics</i> , 2001 , 3, 133-43	3	128
377	Identification of TMEM230 mutations in familial Parkinson's disease. <i>Nature Genetics</i> , 2016 , 48, 733-9	36.3	122
376	Outcome after Stereotactic Thalamotomy for Dystonia and Hemiballismus. <i>Neurosurgery</i> , 1995 , 36, 501-508	5.08	121
375	Parkinson's disease: etiopathogenesis and treatment. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 795-808	5.5	120
374	Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. <i>Movement Disorders</i> , 2000 , 15, 678-82	7	120
373	Botulinum toxin: State of the art. <i>Movement Disorders</i> , 2017 , 32, 1131-1138	7	118
372	Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. <i>Archives of Neurology</i> , 2007 , 64, 676-82		118
371	Stiff-person syndrome: an autoimmune disease. <i>Movement Disorders</i> , 1991 , 6, 12-20	7	118
370	Dystonia. <i>Nature Reviews Disease Primers</i> , 2018 , 4, 25	51.1	117
369	Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2017 , 74, 216-224	17.2	116
368	Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. <i>Movement Disorders</i> , 1989 , 4, 157-75	7	115
367	Botulinum toxin: Historical perspective and potential new indications. <i>Muscle and Nerve</i> , 1997 , 20, 129-145	3.4	113
366	Evidence that a gene for essential tremor maps to chromosome 2p in four families. <i>Movement Disorders</i> , 1998 , 13, 972-7	7	111
365	Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 1509-23	4.3	109

364	Botulinum toxin in the treatment of dystonic tics. <i>Movement Disorders</i> , 1994 , 9, 347-9	7	106
363	Tourettism associated with Huntington's disease. <i>Movement Disorders</i> , 1995 , 10, 103-5	7	106
362	Stiff-person syndrome: insights into a complex autoimmune disorder. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 840-8	5.5	105
361	Parkinson disease and the immune system - associations, mechanisms and therapeutics. <i>Nature Reviews Neurology</i> , 2020 , 16, 303-318	15	105
360	Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN [®] , botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. <i>Journal of the Neurological Sciences</i> , 2011 , 308, 103-9	3.2	105
359	Medical treatment of dystonia. <i>Movement Disorders</i> , 2013 , 28, 1001-12	7	104
358	Severe motor tics causing cervical myelopathy in Tourette's syndrome. <i>Movement Disorders</i> , 1996 , 11, 563-6	7	99
357	Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea. <i>JAMA Neurology</i> , 2017 , 74, 977-982	17.2	96
356	Relationship between various clinical outcome assessments in patients with blepharospasm. <i>Movement Disorders</i> , 2009 , 24, 407-13	7	92
355	Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. <i>Neurology</i> , 2019 , 92, 907-915	6.5	91
354	Low cancer rates among patients with Parkinson's disease. <i>Annals of Neurology</i> , 1985 , 17, 505-9	9.4	91
353	Cocaine-related movement disorders. <i>Movement Disorders</i> , 1993 , 8, 175-8	7	90
352	Treatment of cervical dystonia with botulinum toxin. <i>Movement Disorders</i> , 2004 , 19 Suppl 8, S109-15	7	89
351	Motor, behavioral and pharmacologic findings in Tourette's syndrome. <i>Canadian Journal of Neurological Sciences</i> , 1987 , 14, 541-6	1	89
350	Dopamine depleters in the treatment of hyperkinetic movement disorders. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 2461-2470	4	87
349	Copy number variation in obsessive-compulsive disorder and tourette syndrome: a cross-disorder study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014 , 53, 910-9	7.2	86
348	Epigenetic mechanisms in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2015 , 349, 3-9	3.2	83
347	Tardive tremor. <i>Movement Disorders</i> , 1992 , 7, 53-7	7	82

346	Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. <i>Movement Disorders</i> , 1998 , 13, 150-4	7	81
345	Parkinsonism, movement disorders and genetics in frontotemporal dementia. <i>Nature Reviews Neurology</i> , 2016 , 12, 175-85	15	80
344	Intrathecal baclofen for dystonia. <i>Movement Disorders</i> , 2001 , 16, 1201-2	7	77
343	Botulinum toxin therapy for cervical dystonia. <i>Neurotoxicity Research</i> , 2006 , 9, 145-8	4.3	76
342	A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. <i>Neurology</i> , 2017 , 88, 152-159	6.5	75
341	The therapeutic potential of cannabinoids for movement disorders. <i>Movement Disorders</i> , 2015 , 30, 313-27		75
340	Deep brain stimulation for Tourette syndrome: target selection. <i>Stereotactic and Functional Neurosurgery</i> , 2012 , 90, 213-24	1.6	75
339	Disease-oriented approach to botulinum toxin use. <i>Toxicon</i> , 2009 , 54, 614-23	2.8	75
338	Levodopa strengths and weaknesses. <i>Neurology</i> , 2002 , 58, S19-32	6.5	75
337	Distinguishing psychogenic and essential tremor. <i>Journal of the Neurological Sciences</i> , 2007 , 263, 94-9	3.2	74
336	Runner's dystonia. <i>Journal of the Neurological Sciences</i> , 2006 , 251, 73-6	3.2	74
335	Bilateral hemifacial spasm: a report of five cases and a literature review. <i>Movement Disorders</i> , 1999 , 14, 345-9	7	74
334	Dystonic tics in patients with Tourette's syndrome. <i>Movement Disorders</i> , 1991 , 6, 248-52	7	74
333	Pathogenesis and pathophysiology of functional (psychogenic) movement disorders. <i>Neurobiology of Disease</i> , 2019 , 127, 32-44	7.5	73
332	Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2015 , 2, e130	9.1	73
331	The relationship between essential tremor and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016 , 22 Suppl 1, S162-5	3.6	73
330	Peripheral trauma and movement disorders: a systematic review of reported cases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 892-8	5.5	73
329	Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome. <i>Movement Disorders</i> , 1996 , 11, 431-3	7	73

328	Psychogenic tremor: long-term outcome. <i>CNS Spectrums</i> , 2006 , 11, 501-8	1.8	71
327	Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. <i>Toxicon</i> , 2014 , 90, 344-8	2.8	70
326	Peripherally induced movement disorders. <i>Neurologic Clinics</i> , 2009 , 27, 821-32, vii	4.5	70
325	Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 142-8	3.6	69
324	Effects of Auditory Rhythm and Music on Gait Disturbances in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2015 , 6, 234	4.1	69
323	Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. <i>Brain</i> , 2020 , 143, 234-248	11.2	69
322	Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. <i>Drugs</i> , 2016 , 76, 759-77	12.1	66
321	Dystonia in corticobasal degeneration. <i>Movement Disorders</i> , 2001 , 16, 252-7	7	65
320	The VPS35 gene and Parkinson's disease. <i>Movement Disorders</i> , 2013 , 28, 569-75	7	64
319	Tardive dyskinesia and other movement disorders secondary to aripiprazole. <i>Movement Disorders</i> , 2011 , 26, 147-52	7	64
318	Essential tremor among children. <i>Pediatrics</i> , 2004 , 114, 1203-5	7.4	62
317	Diagnosis and Management of Parkinson's Disease. <i>Seminars in Neurology</i> , 2017 , 37, 118-126	3.2	61
316	Long-term efficacy and safety of botulinum toxin injections in dystonia. <i>Toxins</i> , 2013 , 5, 249-66	4.9	61
315	Orthostatic tremor: an association with essential tremor. <i>Movement Disorders</i> , 1991 , 6, 60-4	7	61
314	Movement disorders induced by deep brain stimulation. <i>Parkinsonism and Related Disorders</i> , 2016 , 25, 1-9	3.6	60
313	Are dopamine receptor agonists neuroprotective in Parkinson's disease?. <i>Drugs and Aging</i> , 2001 , 18, 389-96	4.6	60
312	Autoimmune and paraneoplastic movement disorders: An update. <i>Journal of the Neurological Sciences</i> , 2018 , 385, 175-184	3.2	59
311	Hereditary motor-sensory neuropathy and movement disorders. <i>Muscle and Nerve</i> , 1993 , 16, 904-10	3.4	59

310	Treatable inherited rare movement disorders. <i>Movement Disorders</i> , 2018 , 33, 21-35	7	57
309	An update on new and unique uses of botulinum toxin in movement disorders. <i>Toxicon</i> , 2018 , 147, 84-88	2.8	57
308	Genome-wide association study in essential tremor identifies three new loci. <i>Brain</i> , 2016 , 139, 3163-3169	1.2	57
307	Genetic testing in Parkinson disease: promises and pitfalls. <i>Archives of Neurology</i> , 2006 , 63, 1232-7		57
306	Bruxism in Huntington's disease. <i>Movement Disorders</i> , 2000 , 15, 171-3	7	57
305	The phenomenology of tics. <i>Movement Disorders</i> , 1986 , 1, 17-26	7	57
304	Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. <i>Movement Disorders</i> , 2011 , 26, 1521-8	7	56
303	Rotenone affects p53 transcriptional activity and apoptosis via targeting SIRT1 and H3K9 acetylation in SH-SY5Y cells. <i>Journal of Neurochemistry</i> , 2015 , 134, 668-76	6	55
302	ADCY5-related movement disorders: Frequency, disease course and phenotypic variability in a cohort of paediatric patients. <i>Parkinsonism and Related Disorders</i> , 2017 , 41, 37-43	3.6	54
301	Tardive syndromes. <i>Journal of the Neurological Sciences</i> , 2018 , 389, 35-42	3.2	54
300	Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is rarely required. <i>Muscle and Nerve</i> , 2001 , 24, 1568-70	3.4	54
299	Anosmia and Ageusia in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017 , 133, 541-556	4.4	53
298	Psychiatric associations of adult-onset focal dystonia phenotypes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 595-602	5.5	52
297	Whole-Exome Sequencing in Familial Parkinson Disease. <i>JAMA Neurology</i> , 2016 , 73, 68-75	17.2	52
296	Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxinA efficacy (CD PROBE). <i>Journal of the Neurological Sciences</i> , 2015 , 349, 84-93	3.2	52
295	Neuroprotection by Orexin-A via HIF-1 α induction in a cellular model of Parkinson's disease. <i>Neuroscience Letters</i> , 2014 , 579, 35-40	3.3	51
294	Alleviating manoeuvres (sensory tricks) in cervical dystonia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 882-4	5.5	50
293	Tourette's syndrome in adults. <i>Movement Disorders</i> , 2010 , 25, 2171-5	7	50

292	Immunogenicity Associated with Botulinum Toxin Treatment. <i>Toxins</i> , 2019 , 11,	4.9	49
291	Restless legs syndrome: clinical presentation diagnosis and treatment. <i>Sleep Medicine</i> , 2015 , 16, 678-90	4.6	49
290	Movement disorders in musicians. <i>Movement Disorders</i> , 2008 , 23, 1957-65	7	49
289	Treatment of palatal myoclonus with sumatriptan. <i>Movement Disorders</i> , 1996 , 11, 748-51	7	49
288	Paroxysmal movement disorders. <i>Neurologic Clinics</i> , 2015 , 33, 137-52	4.5	48
287	Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. <i>Movement Disorders</i> , 2014 , 29, 126-30	7	48
286	Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia. <i>Drugs</i> , 2016 , 76, 779-87	12.1	47
285	Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm. <i>Journal of Neural Transmission</i> , 2013 , 120, 1345-53	4.3	46
284	Parkinsonism-plus syndromes. <i>Movement Disorders</i> , 1989 , 4 Suppl 1, S95-119	7	46
283	Parkinsonism and acquired hydrocephalus. <i>Movement Disorders</i> , 1986 , 1, 59-64	7	46
282	A Pilot Study of a Cognitive-Behavioral Treatment for Anxiety and Depression in Patients With Parkinson Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2015 , 28, 210-7	3.8	45
281	Familial essential tremor in 4 kindreds. Prospects for genetic mapping. <i>Archives of Neurology</i> , 1997 , 54, 289-94		44
280	Tics secondary to craniocerebral trauma. <i>Movement Disorders</i> , 1997 , 12, 776-82	7	44
279	Blepharospasm and autoimmune diseases. <i>Movement Disorders</i> , 1987 , 2, 159-63	7	44
278	Targeting β Synuclein in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapeutics. <i>Drugs</i> , 2019 , 79, 797-810	12.1	42
277	The nosology of tardive syndromes. <i>Journal of the Neurological Sciences</i> , 2018 , 389, 10-16	3.2	42
276	Recent Advances in Understanding and Managing Tourette Syndrome. <i>F1000Research</i> , 2016 , 5,	3.6	42
275	Thalamic DBS with a constant-current device in essential tremor: A controlled clinical trial. <i>Parkinsonism and Related Disorders</i> , 2017 , 40, 18-26	3.6	41

274	Alcohol in essential tremor and other movement disorders. <i>Movement Disorders</i> , 2010 , 25, 2274-84	7	41
273	Movement and reaction times and fine coordination tasks following pallidotomy. <i>Movement Disorders</i> , 1999 , 14, 57-62	7	41
272	Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. <i>Movement Disorders</i> , 1989 , 4, 303-9	7	41
271	Deutetrabenazine in Tics Associated with Tourette Syndrome. <i>Tremor and Other Hyperkinetic Movements</i> , 2020 , 6, 422	2	41
270	Essential tremor-plus: a controversial new concept. <i>Lancet Neurology, The</i> , 2020 , 19, 266-270	24.1	41
269	Psychogenic movement disorders. <i>Neurologic Clinics</i> , 2015 , 33, 205-24	4.5	40
268	Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. <i>Movement Disorders</i> , 2015 , 30, 1885-92	7	40
267	Cervical dystonia associated with tumors of the posterior fossa. <i>Movement Disorders</i> , 1997 , 12, 443-7	7	40
266	Chorea associated with Huntington's disease: to treat or not to treat?. <i>Movement Disorders</i> , 2014 , 29, 1414-8	7	39
265	Re-emergence of childhood stuttering in Parkinson's disease: a hypothesis. <i>Movement Disorders</i> , 2001 , 16, 114-8	7	39
264	Progressive Supranuclear Palsy. <i>Canadian Journal of Neurological Sciences</i> , 1987 , 14, 547-554	1	39
263	Diagnosis and treatment of psychogenic parkinsonism. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 1300-3	5.5	38
262	Outcome measurement in functional neurological disorder: a systematic review and recommendations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 638-649	5.5	37
261	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology, The</i> , 2020 , 19, 71-80	24.1	37
260	Gait disorders. <i>Neurologic Clinics</i> , 2015 , 33, 249-68	4.5	36
259	Tardive myoclonus. <i>Movement Disorders</i> , 1987 , 2, 307-11	7	36
258	Huntington disease: A quarter century of progress since the gene discovery. <i>Journal of the Neurological Sciences</i> , 2019 , 396, 52-68	3.2	36
257	Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo-controlled crossover study. <i>Movement Disorders</i> , 2018 , 33, 1272-1280	7	36

256	Accuracy of the clinical diagnosis of postencephalitic parkinsonism: a clinicopathologic study. <i>European Journal of Neurology</i> , 1998 , 5, 451-457	6	35
255	Onabotulinum toxin-A injections for sleep bruxism: A double-blind, placebo-controlled study. <i>Neurology</i> , 2018 , 90, e559-e564	6.5	34
254	Local field potentials of subthalamic nucleus contain electrophysiological footprints of motor subtypes of Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E8567-E8576	11.5	34
253	Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease. <i>Movement Disorders</i> , 2017 , 32, 433-440	7	34
252	Atomoxetine for freezing of gait in Parkinson disease. <i>Journal of the Neurological Sciences</i> , 2009 , 284, 177-8	3.2	34
251	Tardive dystonia in patients with Tourette's syndrome. <i>Movement Disorders</i> , 1988 , 3, 274-80	7	34
250	IncobotulinumtoxinA (Xeomin) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. <i>Journal of the Neurological Sciences</i> , 2014 , 346, 116-20	3.2	33
249	Outcome Measures for Functional Neurological Disorder: A Review of the Theoretical Complexities. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020 , 32, 33-42	2.7	33
248	Muscle mitochondrial ATP production in progressive supranuclear palsy. <i>Journal of Neurochemistry</i> , 1994 , 62, 1631-4	6	32
247	Sulpiride-induced tardive dystonia. <i>Movement Disorders</i> , 1990 , 5, 83-4	7	32
246	Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. <i>Parkinsonism and Related Disorders</i> , 2019 , 67, 74-89	3.6	31
245	Flu-like symptoms following botulinum toxin therapy. <i>Toxicon</i> , 2011 , 58, 1-7	2.8	31
244	Abnormal systemic metabolism of iron, porphyrin, and calcium in Fahr's syndrome. <i>Annals of Neurology</i> , 1989 , 26, 569-75	9.4	31
243	Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments. <i>Neurotherapeutics</i> , 2020 , 17, 1681-1693	6.4	31
242	Classification of paroxysmal dyskinesias and ataxias. <i>Advances in Neurology</i> , 2002 , 89, 387-400		31
241	New and emerging medical therapies in Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 895-909	4	30
240	Are psychogenic non-epileptic seizures just another symptom of conversion disorder?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 425-429	5.5	29
239	Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. <i>JAMA Neurology</i> , 2016 , 73, 102-10	17.2	29

238	Evidence-based review of patient-reported outcomes with botulinum toxin type A. <i>Clinical Neuropharmacology</i> , 2004 , 27, 234-44	1.4	29
237	Thalamic deep brain stimulation: effects on the nontarget limbs. <i>Movement Disorders</i> , 2001 , 16, 1137-427		29
236	Essential Tremor and Parkinson's Disease: Exploring the Relationship. <i>Tremor and Other Hyperkinetic Movements</i> , 2018 , 8, 589	2	29
235	Media hype: Patient and scientific perspectives on misleading medical news. <i>Movement Disorders</i> , 2017 , 32, 1319-1323	7	28
234	Botulinum Toxin for the Treatment of Hand Tremor. <i>Toxins</i> , 2018 , 10,	4.9	28
233	A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease. <i>Movement Disorders</i> , 1999 , 14, 664-8	7	28
232	Persistent dystonia possibly induced by flecainide. <i>Movement Disorders</i> , 1992 , 7, 62-3	7	28
231	Essential Tremor and Parkinson's Disease: Exploring the Relationship. <i>Tremor and Other Hyperkinetic Movements</i> , 2020 , 8, 589	2	28
230	Consensus for the measurement of the camptocormia angle in the standing patient. <i>Parkinsonism and Related Disorders</i> , 2018 , 52, 1-5	3.6	27
229	Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 640-3	3.6	27
228	Therapeutic Developments for Tics and Myoclonus. <i>Movement Disorders</i> , 2015 , 30, 1566-73	7	27
227	Deutetrabenazine in Tics Associated with Tourette Syndrome. <i>Tremor and Other Hyperkinetic Movements</i> , 2016 , 6, 422	2	27
226	Botulinum Toxin in Movement Disorders: An Update. <i>Toxins</i> , 2021 , 13,	4.9	27
225	Dystonia: medical therapy and botulinum toxin. <i>Advances in Neurology</i> , 2004 , 94, 275-86		27
224	Speech and voice disorders in patients with psychogenic movement disorders. <i>Journal of Neurology</i> , 2015 , 262, 2420-4	5.5	26
223	Movement disorders in catatonia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 825-32	5.5	26
222	Hereditary myoclonus and progressive distal muscular atrophy. <i>Annals of Neurology</i> , 1979 , 6, 227-31	9.4	26
221	Autosomal dominant mitochondrial membrane protein-associated neurodegeneration (MPAN). <i>Molecular Genetics & Genomic Medicine</i> , 2019 , 7, e00736	2.3	25

220	Genetic mouse models of essential tremor: are they essential?. <i>Journal of Clinical Investigation</i> , 2005 , 115, 584-6	15.9	25
219	Pathogenesis-targeted therapeutic strategies in Parkinson's disease. <i>Movement Disorders</i> , 2019 , 34, 41-44		25
218	The future of research in Parkinson disease. <i>JAMA Neurology</i> , 2014 , 71, 1351-2	17.2	24
217	Young-onset Parkinson's disease: Its unique features and their impact on quality of life. <i>Parkinsonism and Related Disorders</i> , 2019 , 65, 39-48	3.6	23
216	Botulinum Toxin for the Treatment of Tremor and Tics. <i>Seminars in Neurology</i> , 2016 , 36, 54-63	3.2	23
215	Research Priorities in Limb and Task-Specific Dystonias. <i>Frontiers in Neurology</i> , 2017 , 8, 170	4.1	23
214	Genetics and molecular biology of brain calcification. <i>Ageing Research Reviews</i> , 2015 , 22, 20-38	12	23
213	Tourette's syndrome and the law. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2006 , 18, 86-95	2.7	23
212	Niemann-Pick disease type C: two cases and an update. <i>Movement Disorders</i> , 2000 , 15, 1199-203	7	23
211	Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. <i>Drugs</i> , 2018 , 78, 525-541	12.1	22
210	Increased Incidence of Functional (Psychogenic) Movement Disorders in Children and Adults Amid the COVID-19 Pandemic: A Cross-sectional Study. <i>Neurology: Clinical Practice</i> , 2021 , 11, e686-e690	1.7	22
209	Clinimetric testing of the comprehensive cervical dystonia rating scale. <i>Movement Disorders</i> , 2016 , 31, 563-9	7	22
208	Movement Disorders From the Use of Metoclopramide and Other Antiemetics in the Treatment of Migraine. <i>Headache</i> , 2016 , 56, 153-61	4.2	22
207	Dystonia and Tremor: A Cross-Sectional Study of the Dystonia Coalition Cohort. <i>Neurology</i> , 2021 , 96, e563-e574	6.5	22
206	Movement disorders in 2016: Progress in Parkinson disease and other movement disorders. <i>Nature Reviews Neurology</i> , 2017 , 13, 76-78	15	21
205	Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. <i>Drug Design, Development and Therapy</i> , 2015 , 9, 1913-26	4.4	21
204	Genetic movement disorders in patients of Jewish ancestry. <i>JAMA Neurology</i> , 2014 , 71, 1567-72	17.2	21
203	Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis. <i>Movement Disorders</i> , 2006 , 21, 1500-2	7	21

202	Case 1, 1995: psychosis, dementia, chorea, ataxia, and supranuclear gaze dysfunction. <i>Movement Disorders</i> , 1995 , 10, 257-62	7	21
201	International Classification of Diseases, tenth revision: neurological adaptation (ICD-10 NA): extrapyramidal and movement disorders. <i>Movement Disorders</i> , 1995 , 10, 533-40	7	21
200	Botulinum toxin for the treatment of tremor. <i>Parkinsonism and Related Disorders</i> , 2019 , 63, 31-41	3.6	20
199	Head tremor at disease onset: an ataxic phenotype of cervical dystonia. <i>Journal of Neurology</i> , 2019 , 266, 1844-1851	5.5	20
198	Progress in research on Tourette syndrome. <i>Journal of Obsessive-Compulsive and Related Disorders</i> , 2014 , 3, 359-362	1.7	20
197	Parkinson's disease and movement disorders: moving forward. <i>Lancet Neurology</i> , 2008 , 7, 9-11	24.1	20
196	An update on the treatment of Parkinson's disease. <i>Mount Sinai Journal of Medicine</i> , 2006 , 73, 682-9		20
195	Apraclonidine in the treatment of ptosis. <i>Journal of the Neurological Sciences</i> , 2017 , 376, 129-132	3.2	19
194	Improvement in dystonic camptocormia following botulinum toxin injection to the external oblique muscle. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 1106-7	3.6	19
193	"Psychogenic" versus "functional" movement disorders? That is the question. <i>Movement Disorders</i> , 2014 , 29, 1697-8	7	19
192	Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). <i>BMC Neurology</i> , 2011 , 11, 140	3.1	19
191	Focal dystonia: the role of botulinum toxin. <i>Current Neurology and Neuroscience Reports</i> , 2001 , 1, 337-456.6		19
190	Distinguishing features of psychogenic (functional) versus organic hemifacial spasm. <i>Journal of Neurology</i> , 2017 , 264, 359-363	5.5	18
189	Dopamine transporter imaging in essential tremor with and without parkinsonian features. <i>Journal of Neural Transmission</i> , 2015 , 122, 1515-21	4.3	18
188	Benefits and risks of unilateral and bilateral ventral intermediate nucleus deep brain stimulation for axial essential tremor symptoms. <i>Parkinsonism and Related Disorders</i> , 2019 , 60, 126-132	3.6	18
187	Treatment of tics associated with Tourette syndrome. <i>Journal of Neural Transmission</i> , 2020 , 127, 843-850.3	4.3	17
186	Progress toward an integrated understanding of Parkinson's disease. <i>F1000Research</i> , 2017 , 6, 1121	3.6	17
185	Botulinum toxin for the treatment of cervical dystonia. <i>Expert Opinion on Pharmacotherapy</i> , 2001 , 2, 1985-94	5	17

184	A comparison of postspace-flight orthostatic intolerance to vasovagal syncope and autonomic failure and the potential use of the alpha agonist midodrine for these conditions. <i>Journal of Clinical Pharmacology</i> , 1994 , 34, 466-71	2.9	17
183	Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 1345-51	3.6	16
182	What is it? Case 1, 1994: rapidly progressive aphasia, apraxia, dementia, myoclonus, and parkinsonism. <i>Movement Disorders</i> , 1994 , 9, 358-66	7	16
181	What is it? Case 1, 1993: parkinsonism, dysautonomia, and ophthalmoparesis. <i>Movement Disorders</i> , 1993 , 8, 525-32	7	16
180	Psychogenic tremor: a video guide to its distinguishing features. <i>Tremor and Other Hyperkinetic Movements</i> , 2014 , 4, 253	2	16
179	Parkinson's disease after COVID-19. <i>Journal of the Neurological Sciences</i> , 2021 , 422, 117331	3.2	16
178	Bilateral pallidal deep brain stimulation for X-linked dystonia-parkinsonism. <i>World Neurosurgery</i> , 2014 , 82, 241.e1-4	2.1	15
177	Hemidystonia-hemiatrophy syndrome. <i>Movement Disorders</i> , 2009 , 24, 583-9	7	15
176	Hemifacial spasm and hypertension: how strong is the association?. <i>Movement Disorders</i> , 2000 , 15, 363-57		15
175	Clinical phenotype in carriers of intermediate alleles in the huntingtin gene. <i>Journal of the Neurological Sciences</i> , 2019 , 402, 57-61	3.2	14
174	Tics associated with other disorders. <i>Advances in Neurology</i> , 2006 , 99, 61-8		14
173	Parkinson disease: Exenatide - a drug for diabetes and Parkinson disease?. <i>Nature Reviews Neurology</i> , 2017 , 13, 643-644	15	13
172	Psychogenic Ophthalmologic Movement Disorders. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2016 , 28, 195-8	2.7	13
171	Tetrabenazine for treatment of chorea associated with Huntington's disease and other potential indications. <i>Expert Opinion on Orphan Drugs</i> , 2013 , 1, 423-436	1.1	13
170	Functional gait disorders, clinical phenomenology, and classification. <i>Neurological Sciences</i> , 2020 , 41, 911-915	3.5	13
169	[Essential tremor: genetic update]. <i>Expert Reviews in Molecular Medicine</i> , 2019 , 21, e8	6.7	13
168	Genetic Counseling in Huntington's Disease: Potential New Challenges on Horizon?. <i>Frontiers in Neurology</i> , 2019 , 10, 453	4.1	12
167	Stem Cells: Scientific and Ethical Quandaries of a Personalized Approach to Parkinson's Disease. <i>Movement Disorders</i> , 2020 , 35, 1312-1314	7	12

166	EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 543-558	5.3	12
165	Functional (psychogenic) stereotypies. <i>Journal of Neurology</i> , 2017 , 264, 1482-1487	5.5	12
164	Candidate locus for chorea and tic disorders at 15q?. <i>Pediatric Neurology</i> , 2007 , 37, 70-3	2.9	12
163	Dystonia and cerebellar ataxia. <i>Movement Disorders</i> , 1990 , 5, 178	7	12
162	Tremor Syndromes: An Updated Review. <i>Frontiers in Neurology</i> , 2021 , 12, 684835	4.1	12
161	Botulinum toxin: Historical perspective and potential new indications 1997 , 20, 129		12
160	Treatment of Tardive Dyskinesia. <i>Neurologic Clinics</i> , 2020 , 38, 379-396	4.5	11
159	Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. <i>Movement Disorders</i> , 2018 , 33, 468-472	7	11
158	Deutetrabenazine for the treatment of Huntington's chorea. <i>Expert Review of Neurotherapeutics</i> , 2018 , 18, 625-631	4.3	11
157	Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?. <i>Parkinsonism and Related Disorders</i> , 2019 , 69, 34-39	3.6	11
156	Treatment of blepharospasm with apraclonidine. <i>Journal of the Neurological Sciences</i> , 2017 , 372, 57-59	3.2	11
155	Parkinson's disease in monozygotic twins. <i>Annals of Neurology</i> , 1986 , 19, 405-8	9.4	11
154	Upper facial chorea in Huntington disease. <i>Journal of Clinical Movement Disorders</i> , 2014 , 1, 7	2.8	10
153	Effect of tetrabenazine on motor function in patients with huntington disease. <i>Neurology and Therapy</i> , 2012 , 1, 5	4.6	10
152	Reply to: Treatment of tics in patients with Tourette syndrome: Recommendations according to the European Society for the Study of Tourette Syndrome. <i>Movement Disorders</i> , 2011 , 26, 2448-2448	7	10
151	Post-Traumatic Movement Disorders: Effect of the Legal System on Outcome. <i>Journal of Forensic Sciences</i> , 1998 , 43, 16143J	1.8	10
150	Phenotypic Features of Isolated Essential Tremor, Essential Tremor Plus, and Essential Tremor-Parkinson's Disease in a Movement Disorders Clinic. <i>Tremor and Other Hyperkinetic Movements</i> , 2021 , 11, 12	2	10
149	Parkinson's disease tremors and serotonin. <i>Brain</i> , 2018 , 141, 624-626	11.2	9

148	Leg stereotypy syndrome: phenomenology and prevalence. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 692-695	5.5	9
147	Hemidystonia secondary to carotid artery gunshot injury. <i>Childs Nervous System</i> , 1997 , 13, 285-8	1.7	9
146	Parkinson's disease and skin. <i>Parkinsonism and Related Disorders</i> , 2021 , 82, 61-76	3.6	9
145	Understanding falls in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2017 , 35, 75-83	3.6	8
144	Cervical dystonia and substance abuse. <i>Journal of Neurology</i> , 2018 , 265, 970-975	5.5	8
143	Recent advances in understanding and treatment of Parkinson's disease. <i>Faculty Reviews</i> , 2020 , 9, 6	1.2	8
142	Predictors of alcohol responsiveness in dystonia. <i>Neurology</i> , 2018 , 91, e2020-e2026	6.5	8
141	Counseling At-Risk Parkinson Disease Cohorts: Integrating Emerging Evidence. <i>Current Genetic Medicine Reports</i> , 2017 , 5, 100-107	2.2	7
140	Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study. <i>Journal of the Neurological Sciences</i> , 2019 , 405, 116413	3.2	7
139	Hypertension and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2019 , 66, 166-170	3.6	7
138	Essential Tremor. <i>CNS Drugs</i> , 1996 , 6, 178-191	6.7	7
137	Movement disorders stereotactic surgery for Parkinson's disease. <i>Movement Disorders</i> , 1994 , 9, 470-2	7	7
136	Examiner manoeuvres 'sensory tricks' in functional (psychogenic) movement disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 453-455	5.5	6
135	Available treatment options for dystonia. <i>Expert Opinion on Orphan Drugs</i> , 2017 , 5, 707-716	1.1	6
134	Segmental Myoclonus 2012 , 221-235		6
133	Postural Directionality and Head Tremor in Cervical Dystonia. <i>Tremor and Other Hyperkinetic Movements</i> , 2020 , 10,	2	6
132	Submolecular recognition regions of the H domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. <i>Journal of Neuroimmunology</i> , 2016 , 300, 36-46	3.5	6
131	Quality of life in isolated dystonia: non-motor manifestations matter. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 ,	5.5	6

130	Functional (psychogenic) saccadic oscillations and oculogyric crises. <i>Lancet Neurology, The</i> , 2016 , 15, 791	24.1	5
129	Atypical Alexander disease with dystonia, retinopathy, and a brain mass mimicking astrocytoma. <i>Neurology: Genetics</i> , 2018 , 4, e248	3.8	5
128	Reply: Autopsy-proven Huntington's disease with 29 trinucleotide repeats. <i>Movement Disorders</i> , 2008 , 23, 1793-1793	7	5
127	Case 2, 1988. Congenital mental retardation and juvenile parkinsonism. <i>Movement Disorders</i> , 1988 , 3, 352-61	7	5
126	Integrated sequencing and array comparative genomic hybridization in familial Parkinson disease. <i>Neurology: Genetics</i> , 2020 , 6, e498	3.8	5
125	Head tremor and pain in cervical dystonia. <i>Journal of Neurology</i> , 2021 , 268, 1945-1950	5.5	5
124	Botulinum Neurotoxin Injections in Childhood Opisthotonus. <i>Toxins</i> , 2021 , 13,	4.9	5
123	Neuro-ophthalmology of movement disorders. <i>Expert Review of Ophthalmology</i> , 2018 , 13, 283-292	1.5	5
122	Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. <i>Immunobiology</i> , 2016 , 221, 568-76	3.4	4
121	Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions. <i>Movement Disorders</i> , 2015 , 30, 1862-9	7	4
120	Treatment of superficial siderosis of the central nervous system. <i>Movement Disorders</i> , 1995 , 10, 685	7	4
119	The Role of TMEM230 Gene in Parkinson's Disease. <i>Journal of Parkinsonis Disease</i> , 2018 , 8, 469-477	5.3	4
118	Observational Study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): Interim Results for the First 170 Subjects with Blepharospasm. <i>Tremor and Other Hyperkinetic Movements</i> , 2014 , 4, 238	2	4
117	It's tricky: Rating alleviating maneuvers in cervical dystonia. <i>Journal of the Neurological Sciences</i> , 2020 , 419, 117205	3.2	4
116	Understanding the relationship between freezing of gait and other progressive supranuclear palsy features. <i>Parkinsonism and Related Disorders</i> , 2020 , 78, 56-60	3.6	4
115	Beyond tics: movement disorders in patients with Tourette syndrome. <i>Journal of Neural Transmission</i> , 2021 , 128, 1177-1183	4.3	4
114	"Complex" dystonia is not a category in the new 2013 consensus classification. <i>Movement Disorders</i> , 2016 , 31, 1758-1759	7	4
113	Levodopa-induced dyskinesias in mitochondrial membrane protein-associated neurodegeneration. <i>Neurology: Clinical Practice</i> , 2019 , 9, e7-e9	1.7	4

112	Genome-Wide Association Study Meta-Analysis for Parkinson Disease Motor Subtypes. <i>Neurology: Genetics</i> , 2021 , 7, e557	3.8	4
111	Tetrabenazine in the treatment of Tourette syndrome. <i>Journal of Pediatric Neurology</i> , 2015 , 05, 009-013	0.2	3
110	Clinical and Pathophysiological Features of Cerebellar Dysfunction	2012 , 257-278	3
109	Unique properties of botulinum toxins. <i>Toxicon</i> , 2009 , 54, 675	2.8	3
108	Orthostatic tremor. <i>Movement Disorders</i> , 1991 , 6, 266-7	7	3
107	Association of Essential Tremor With Novel Risk Loci: A Genome-Wide Association Study and Meta-analysis.. <i>JAMA Neurology</i> , 2022 ,	17.2	3
106	Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial. <i>JAMA Network Open</i> , 2021 , 4, e2129397	10.4	3
105	Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial. <i>JAMA Network Open</i> , 2021 , 4, e2128204	10.4	3
104	Treatment of dystonia and tics. <i>Clinical Parkinsonism & Related Disorders</i> , 2020 , 2, 12-19	0.9	3
103	Clinical and Demographic Characteristics of Upper Limb Dystonia. <i>Movement Disorders</i> , 2020 , 35, 2086-2090	0.9	3
102	Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson's disease heterogeneity. <i>Parkinsonism and Related Disorders</i> , 2021 , 84, 105-111	3.6	3
101	Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisal. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 695-705	4.1	3
100	Clinical-Instrumental patterns of neurodegeneration in Essential Tremor: A data-driven approach. <i>Parkinsonism and Related Disorders</i> , 2021 , 87, 124-129	3.6	3
99	Impulse Control Disorders in Parkinson's Disease: Epidemiology, Pathogenesis and Therapeutic Strategies. <i>Frontiers in Psychiatry</i> , 2021 , 12, 635494	5	3
98	The etiopathogenetic and pathophysiological spectrum of parkinsonism. <i>Journal of the Neurological Sciences</i> , 2021 , 120012	3.2	3
97	Self-injurious behavior in Tourette syndrome. <i>Journal of Neurology</i> , 2021 , 1	5.5	3
96	Distinguishing Clinical Features of Hyperkinetic Disorders	1-14	3
95	Tardive Dyskinesias	331-352	3

94	152 Development of Deutetrabenazine as a Potential New Non-Antipsychotic Treatment for Tourette Syndrome in Children and Adolescents. <i>CNS Spectrums</i> , 2020 , 25, 297-297	1.8	2
93	Medical treatment of blepharospasm. <i>Expert Review of Ophthalmology</i> , 2018 , 13, 233-243	1.5	2
92	Sleep-related movement disorders314-332		2
91	Inherited and Sporadic Ataxias 2012 , 279-295		2
90	Psychogenic Movement Disorders 2012 , 375-384		2
89	Essential tremor. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 83	51.1	2
88	Worldwide barriers to genetic testing for movement disorders. <i>European Journal of Neurology</i> , 2021 , 28, 1901-1909	6	2
87	A Multi-center Genome-wide Association Study of Cervical Dystonia. <i>Movement Disorders</i> , 2021 ,	7	2
86	The Clinical Value of Patient Home Videos in Movement Disorders. <i>Tremor and Other Hyperkinetic Movements</i> , 2021 , 11, 37	2	2
85	Primary Dystonias113-134		2
84	Sports-Related Dystonia.. <i>Tremor and Other Hyperkinetic Movements</i> , 2021 , 11, 54	2	2
83	Movement disorders of autoimmune origin52-72		1
82	Influences of HLA DRB1, DQA1 and DQB1 on T-cell recognition of epitopes and of larger regions of the botulinum neurotoxin molecule. <i>Immunology Letters</i> , 2017 , 190, 257-264	4.1	1
81	Statin-related musculoskeletal pain in Parkinson's disease. <i>Pain</i> , 2017 , 158, 1840	8	1
80	Movement disorders in neoplastic brain disease279-292		1
79	Movement disorders in renal diseases172-188		1
78	Paroxysmal Dyskinesias 2012 , 363-374		1
77	Other Tremors 2012 , 95-111		1

76	Animal models of Parkinson disease 2013 , 115-135		1
75	Movement disorders. Preface. <i>Neurologic Clinics</i> , 2009 , 27, ix-x	4.5	1
74	Case 3, 1988. Progressive myoclonic epilepsy, dementia, and blindness in a young girl. <i>Movement Disorders</i> , 1988 , 3, 362-9	7	1
73	Neurodegenerative diseases associated with non-coding CGG tandem repeat expansions.. <i>Nature Reviews Neurology</i> , 2022 ,	15	1
72	A validation of a self-administered screening test for Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2020 , 418, 117116	3.2	1
71	Gene-Environment Interactions in Progressive Supranuclear Palsy. <i>Frontiers in Neurology</i> , 2021 , 12, 664796	1	1
70	Tourette Syndrome and Driving. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 763-768	2.2	1
69	The Wide Spectrum of Functional Movement Disorders. <i>JAMA Neurology</i> , 2019 , 76, 235-236	17.2	1
68	Medical treatment of the motor features of Parkinson disease 2021 , 164-203.e14		1
67	Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects. <i>Current Medical Research and Opinion</i> , 2021 , 37, 1761-1768	2.5	1
66	Exploring the role of botulinum toxin in critical care. <i>Expert Review of Neurotherapeutics</i> , 2021 , 21, 881-894	14	1
65	Predictive modeling of spread in adult-onset isolated dystonia: Key properties and effect of tremor inclusion. <i>European Journal of Neurology</i> , 2021 , 28, 3999-4009	6	1
64	Parkinsonism and tremor syndromes. <i>Journal of the Neurological Sciences</i> , 2021 , 120018	3.2	1
63	Movement and reaction times and fine coordination tasks following pallidotomy 1999 , 14, 57		1
62	Essential Tremor71-94		1
61	Slowing Parkinson's Disease Progression with Vaccination and Other Immunotherapies.. <i>CNS Drugs</i> , 2022 , 36, 327	6.7	1
60	The clinical phenomenology and correlations of oculogyric tics.. <i>Acta Neurologica Belgica</i> , 2022 , 1	1.5	1
59	Dystonic motor and phonic tics in Tourette syndrome.. <i>Journal of Neurology</i> , 2022 , 1	5.5	1

58	Movement disorders in endocrinological diseases131-143		o
57	Head tremor in cervical dystonia: Quantifying severity with computer vision.. <i>Journal of the Neurological Sciences</i> , 2022 , 434, 120154	3.2	o
56	Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. <i>Parkinsonism and Related Disorders</i> , 2020 , 77, 141-145	3.6	o
55	Does Raising the Arms Modify Head Tremor Severity in Cervical Dystonia?. <i>Tremor and Other Hyperkinetic Movements</i> , 2021 , 11, 21	2	o
54	Diagnostic criteria for blepharospasm: A multicenter international study. <i>Parkinsonism and Related Disorders</i> , 2021 , 91, 109-114	3.6	o
53	Cervical dystonia: an update on therapeutics. <i>Expert Opinion on Orphan Drugs</i> , 2019 , 7, 199-209	1.1	
52	Response to Shill and colleagues. <i>Parkinsonism and Related Disorders</i> , 2016 , 23, 108	3.6	
51	The use of botulinum neurotoxin in tic disorders and essential hand and head tremor160-167		
50	Movement disorders associated with chronic metal poisoning220-233		
49	Movement disorders following non-metal intoxications234-246		
48	Dysautonomia in movement disorders363-382		
47	Gastrointestinal complications of movement disorders383-397		
46	Respiratory complications of movement disorders398-418		
45	Movement disorders in hematological disease189-202		
44	Drug-induced movement disorders203-219		
43	Movement disorders in stroke247-267		
42	Phenomenology, classification, and diagnostic approach to patients with movement disorders1-15		
41	Pathogenesis of movement disorders: basic neuroanatomy and pathophysiology16-30		

40 Principles of management in movement disorders 31-38

39 Paraneoplastic movement disorders 39-51

38 Movement disorders in systemic infections 73-88

37 Movement disorders in HIV- and AIDS-related central nervous system infections 89-98

36 Movement disorders in metabolic diseases in adulthood 99-114

35 Movement disorders in childhood metabolic diseases 115-130

34 Movement disorders in multiple sclerosis 268-278

33 The borderland between epilepsy and movement disorders 333-351

32 Movement disorders in liver disease 144-171

31 Movement disorders in encephalitis 293-313

30 Movement disorders associated with neuromuscular disorders and peripheral neuropathies 352-362

29 Movement disorders emergencies 419-441

28 Secondary Dystonias **2012**, 135-145

27 Acquired Chorea **2012**, 175-187

26 Inherited Myoclonus Syndromes **2012**, 207-220

25 Pathophysiology and Molecular Pathology of Dystonia and Tics **2012**, 15-25

24 Ask the Experts: Differentiating Parkinson's disease from other parkinsonian disorders **2013**, 136-140

23 Overview of the Medical Treatment of the Non-Motor and Non-Dopaminergic Features of Parkinson's Disease **2011**, 394-408

22 Surgical Treatments of Dystonia **2008**, 241-250

21 Botulinum toxin: primary and secondary resistance45-57

20 Reply: Reflex sympathetic syndrome and peripheral dystonia. *Movement Disorders*, **2003**, 18, 1213-1213 7

19 Tremors **2002**, 513-522

18 The pharmacological treatment of Tourette syndrome. *International Review of Movement Disorders*, **2022**,

17 Coprolalia and Malignant Phonic Tics. *Current Clinical Neurology*, **2022**, 233-239

0.1

16 On secondary tics and tourettism. *Revista Brasileira De Psiquiatria*, **2005**, 27, 163-164

2.6

15 Antiglutamic Acid Decarboxylase 65 Antibody-Associated Hemiataxia. *Neurology: Clinical Practice*, **2021**, 11, e564-e566

1.7

14 Overview of the Medical Treatments of Hyperkinetic Disorders40-48

13 Other Jerks and Startles236-256

12 Pathophysiology and Molecular Pathology of Tremor, Myoclonus, and Chorea26-39

11 Tics and Tourette Syndrome188-199

10 Overview of Surgical Treatment Possibilities in Hyperkinetic Disorders49-69

9 Dyskinesias in Parkinsonian Syndromes297-310

8 Secondary Tics200-205

7 Stereotypies and Other Developmental Hyperkinesias353-362

6 Huntington Disease and Other Genetic Chorea147-174

5 Reply to: "Toward a Personalized Approach to Parkinson's Cell Therapy". *Movement Disorders*, **2020**, 35, 2120-2121

7

4 Tics and Tourette syndrome **2021**, 418-450.e15

3 Tremor **2022**, 305-331

2 Tics and Tourette Syndrome **2022**, 99-140

1 Parkinsonism **2022**, 395-413